Guidance

Bluetongue serotype 3 vaccine advice for veterinarians

Advice from the UK Chief Veterinary Officer to veterinarians prescribing BTV-3 vaccines.

Documents

Advice for veterinarians prescribing BTV-3 vaccines

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

Defra’s Secretary of State has permitted the use of 3 unauthorised bluetongue serotype 3 (BTV-3) vaccines within the United Kingdom, subject to licence. Veterinarians should read the advisory note before prescribing any BTV-3 vaccine.

Although these vaccines are not authorised, the Veterinary Medicines Directorate (VMD) has assessed them. They consider the vaccines to be of a consistent quality and safety, and efficacy has been demonstrated. Therefore, they meet the administration criteria under Schedule 4 of the Veterinary Medicine Regulations 2013 (VMR 2013).

Unlike the authorised vaccines for other BTV serotypes, the BTV-3 vaccines claim to reduce viraemia rather than prevent it. This means they may not prevent animals from being infected or infectious, but (depending on the vaccine) their claims include reduction or prevention of clinical signs experienced or mortality.

As this is the first time that Defra has used this power, the UK Chief Veterinary Officer asks all veterinarians to record all vaccine use and inform relevant authorities of any adverse effects.

For information on how your data is stored see the Exotic, notifiable and reportable diseases privacy notice.

Updates to this page

Published 16 September 2024
Last updated 11 October 2024 + show all updates
  1. Updated the email address that veterinarians should use to notify Defra when they have prescribed a BTV-3 vaccine. They should now email [email protected]

  2. First published.

Sign up for emails or print this page